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Abstract
The main goal of the present study was estimation of an internal contamination of 131I among family members of patients 
treated with radioactive iodine. Thyroid activity measurements of 131I in examined volunteers were performed using a 
whole-body spectrometer at the institute of nuclear physics, Polish academy of sciences. During this research, 20 relatives 
of patients treated with 131I were examined: eight women and 12 men with an age in the range from 3 to 72 years. In the case 
of nine individuals, the activity of 131I in the thyroid was below the detection limit, but among the remaining 11 individuals, 
the activity varied from (9 ± 3) Bq up to (1140 ± 295) Bq. Subsequently, based on the measurements of thyroid 131I activities, 
the corresponding doses were assessed. The highest estimated effective dose reached 218 μSv, while the thyroid equivalent 
dose was 2.4 mSv. In addition, the experimental data obtained were statistically analysed together with the results of surveys 
of the individuals participating in the study by means of correspondence analysis and nonparametric tests: Mann–Whitney, 
gamma, χ2 and Yule Phi coefficient. These analyses revealed relationships between 131I activities in the thyroids of the exam-
ined individuals and their housing conditions as well as consumption of meals prepared by the patients.
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Introduction
Since the very beginning of nuclear medicine (the 30–40 s of 
the 20th century), 131I has been playing a key role. 131I was 
discovered by Glenn Seaborg and John Livingood in 1938 at 
the University of California, Berkeley. The first reports about 
its application in medicine appeared less than eight years 
later, when Hertz and Roberts, and Seidlin and co-workers 
successfully applied 131I in treatment procedures of Graves’ 
disease and thyroid cancer (Hertz and Roberts 1946; Seidlin 
et al. 1946). Currently, 131I is used in thyroid and whole-
body scintigraphy, and in treatment of hyperthyroidism and 
thyroid cancer. In the case of thyroid disease, in Poland, 
single activities of 131I administered to patients are in the 
range from 0.05 mCi (1.85 MBq) in the case of thyroid scin-
tigraphy, up to 250 mCi (9.25 GBq) during cancer treatment.
The above-mentioned medical interventions like scin-
tigraphy and hyperthyroidism treatment allow performing 
limited ambulatory care, which means that after the appli-
cation of 131I, patients may return to their homes. In the 
case of thyroid cancer treatment, it is necessary to isolate 
patients in the hospital for a few days after 131I application 
(usually 3–5 days). In Polish hospitals, during this period, 
constant monitoring of the dose rate from the patient’s 
body is performed. When the dose rate drops below 
5 µSv h−1 at a distance of 2 m, the patient may qualify for 
discharge from hospital. Such a dose rate corresponds to 
an activity of about 400 MBq accumulated in the patient’s 
body. This activity level (400–600 MBq) is used as the 
patient discharge limit in most European Union member 
states (EURATOM 1997; ICRP 2004). Another criterion is 
the dose rate of radiation emitted from the patient’s body. 
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In many European countries (e.g., Germany, and in con-
trast to Poland) the dose rate limit is set at 3.5 µSv h−1 
(measured at a distance of 2 m from the patient) and the 
hospitalization period is set to at least 2 days. Different 
regulations are used in Japan, where the patient can be 
released from hospital if the 131I activity in his body is 
less than 500 MBq or the dose rate measured at a dis-
tance of 1 m is less than 30 µSv h−1. In the United States, 
patients’ release criteria are defined by the US Nuclear 
Regulatory Commission (USNRC 1997a, b). In general, 
release criteria are based on physical half-life, activity or 
dose rate. Based on these criteria, the International Com-
mission on Radiological Protection recommends patients 
to be released from hospital if their residual activity of 131I 
is less than 800 MBq (ICRP 2004). In addition, patients 
should receive basic instructions regarding radiologi-
cal protection, which should be followed after returning 
home. In this context, the most important instructions for 
patients are isolation from other members of the family for 
about 2 weeks, lack of contact with children and pregnant 
women, utilization of their own toilet and kitchen utensils 
as well as special care for personal hygiene and caution 
when urinating.
However, there is a potential risk that patients may 
neglect or even totally desist obeying these radiological 
protection rules. So far, the approach to radiation protection 
of family members’ patients treated with radioactive iodine 
was based only on the assessment of external doses (Mathieu 
et al. 1999; Pant et al. 2005; Kocovska et al. 2011a, b; Zehta-
bian et al. 2017). Nonetheless, 131I is being excreted from 
the patient’s body (mainly in sweat and urine) and easily 
sublimes, which may cause a potential risk that it is inhaled 
relatives and accumulated in their thyroids. Consequently, 
the main goal of the present study was an estimation of 
internal contamination with 131I among family members of 




In this study, 20 relatives of patients treated with 131I were 
examined: eight women and 12 men at an age in the range 
from 3 to 72 years. These individuals were family mem-
bers of patients treated for hyperthyroidism (six cases) 
or thyroid cancer (14 cases). Predominantly, they were 
patients’ partners or children (four children under 18 years 
of age). The study was approved by the Bioethics Commit-
tee at the Regional Chambers of Physicians and Dentists 
in Krakow, Poland (decision number 111/KBL/OIL/2015, 
dated 09.09.2015).
131I activity measurements
Thyroid activity measurements of 131I in examined volun-
teers were performed using the whole-body spectrometer 
at the Institute of Nuclear Physics, Polish Academy of Sci-
ences. The shielding of the spectrometer was purposely 
designed allowing to place and measure the whole body of 
an adult person: the shielding is 2 m long, 1.2 m wide and 
1.3 m high. The shield is made of steel from the 19th cen-
tury, free from 60Co traces to keep radiation background 
low, and the thickness of its walls is about 17 cm, while its 
mass is about 18 tons (Mietelski et al. 2013).
The activity of 131I was measured using a low-back-
ground gamma-ray spectrometer equipped with an n-type 
germanium detector (HPGe, GMX-30190-P by Ortec with 
30% relative efficiency). Data acquisition and analysis 
were performed using Canberra equipment and software 
(Multiport II, Genie-2000). Quantification of 131I activity 
in thyroids was carried out by measuring the 364.49 keV 
gamma-line.
Calibration of the detector was performed with an adult 
human thyroid phantom containing an 131I solution with an 
activity of 6 kBq ± 0.6%. The dimensions of the phantom 
are 5.5 cm long, 2.5 cm wide and 2 cm high. The average 
detector efficiency was estimated to be (0.31 ± 0.08) %. 
The estimated uncertainty is relatively high, namely 25%, 
because it takes into account the large uncertainty due to 
the relative position of the thyroid gland and the detector 
(Kierepko et al. 2014). This high uncertainty of the effi-
ciency propagates to a relatively high uncertainty of 131I 
activity in the thyroid gland.
A single measurement lasted about 60 min, and the 
detector was placed from 2 to 4 cm from thesurface of the 
neck. Typically, in the measurements a limit of detection 
(LOD) of about 4–6 Bq was achieved, depending on the 
measurement parameters described above. Measurements 
of 131I activity in relatives’ thyroids were performed 7 days 
after discharge of patients from hospital.
Questionnaire surveys
Every person who took part in the study was asked to com-
plete a questionnaire that consisted of four main parts. The 
first part included general questions about height, weight 
and gender, while the second part described frequency 
and character of interactions with the treated person. The 
third part focused on housing conditions like living in 
the city or on the countryside, living in a single-family 
house or in a flat, surface area of apartment, number of 
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rooms or bathroom sharing with the patient. In the last part 
the participants were asked about their food habits (e.g., 
whether they consumed meals prepared by patient). Apart 
from anthropometric parameters, all other data from the 
questionnaire were strictly categorized by assigning them 
either logical values: yes = 1 or no = 0 (for dichotomous 
variables), or more numerically ordered values (for mul-
tilevel variables), thus bringing about dichotomous and 
multilevel categorical parameters, respectively.
Statistical approach
To quantify any dependencies between the investigated 
parameters, 20 complete survey forms were studied with 
a statistical correspondence analysis (CA) method. The 
nominal or ordinal data from the questionnaire (the dichot-
omous and multilevel categorical parameters mentioned 
above) were gathered in a contingency table together with 
the thyroid activities measured in the individuals. The 
results on 131I activity were then transformed into an ordi-
nal scale (four categories) according to the following algo-
rithm: (1) low activities (< 11 Bq), (2) moderate activities 
(≥ 11 Bq and < 150 Bq), (3) elevated activities (≥ 150 Bq 
and < 600 Bq), (4) highly elevated values (> 1100 Bq). 
All these parameters formed a multidimensional space of 
original scores. The analyses of coordinates of the dichot-
omous and multilevel categorical parameters in the coor-
dinate system of the CA model, generated in the reduced 
(two-dimensional) space determined by the first two new 
dimensions of this model, allowed to reveal the structure 
of associations between parameters. In this work, CA was 
constructed under the condition that its first two dimen-
sions should explain at least 50% of the total inertia in the 
original set of parameters. Thus, the parameters or their 
categories with the lowest quality of representation were 
subsequently discarded as well as associations in the CA 
model depending only on single coincidence. Those param-
eters with large absolute values of their coordinates (> 0.3) 
in the CA model were assumed to be associated with one 
another. To express the strength of bivariate associations, 
for the pairs of associated parameters, the algebraic prod-
ucts of their corresponding coordinates and cosine of the 
corresponding angle were calculated (these coefficients are 
called the association weights). The “corresponding angle” 
was defined as the angle determined by two lines connecting 
the origin with coordinates of both parameters on the CA 
coordinates plot. Apart from CA, the gamma correlations 
(Rγ) were computed for the pairs of categorical multilevel 
variables, while for dichotomous variables the χ2 test and 
Yule Phi coefficient were calculated. For thyroid activities, 
categories (2), (3) and (4) were combined, thus, this variable 
became a dichotomous one. The difference of thyroid activi-
ties (categorized into four groups) between family members 
of patients either with cancer or with hyperthyroidism was 
checked using the Mann–Whitney U test. To estimate the 
mean values of thyroid activities in the above-mentioned 
two groups of family members, data were transformed in 
logarithms and retransformed after calculation, because the 
parameter had a non-Gaussian distribution. Therefore, the 
data are shown as mean and confidence interval. In the cal-
culations, the data below the LOD were substituted with the 
value of LOD × 2−0.5.
The statistical analyses were carried out using the STA-
TISTICA v. 12 package (Statsoft, Tulsa, OK, USA) and the 
software delivered by MP System Co. (Chrzanów, Poland). 
The latter was used to calculate correlation weights for the 
pairs of parameters in the CA model.
Doses estimation
In the case of individuals with detected 131I in the thyroid 
gland, complete uptake of 131I by the respiratory system as 
well as its activities in other organs were calculated. Calcula-
tions were based on the iodine biokinetics model developed 
by Leggett (Leggett 2010, 2017) in combination with the 
Human Respiratory Tract Model (ICRP 1994, 2002) and 
the Gastrointestinal Tract Model (ICRP 1979) developed by 
the International Commission on Radiological Protection 
(ICRP). For computer modeling, the SAAM II software from 
Epsilon Group was used (Barrett et al. 1998). The method 
used to calculate radiation doses was presented in detail in 
previous papers (Li 2018; Brudecki et al. 2014, 2017a, b, 
2018a, b, 2019).
Results and discussion
In the present study, 20 individuals, i.e., relatives of patients 
treated with 131I, were examined. Results above the detec-
tion limit were obtained in 11 cases (55%), and they were 
in the range (9 ± 3) Bq up to (1140 ± 295) Bq. The exact 
results are presented in Table 1. These individuals were 
family members of patients treated for hyperthyroidism (six 
cases) or thyroid cancer (14 cases). Among the first group, 
results above detection limit were achieved for four individu-
als (67%), and the mean 131I activity for them was 41.7 Bq 
with a 95% confidence interval of (4.6; 376.0) Bq. Values 
above the detection limit in the second group were observed 
in seven cases (50%) with an average value 14.7 Bq and a 
95% confidence interval of (2.3; 94.5) Bq.
As can be also inferred from Table 1, four children and 16 
adults took part in this study. In the group of adults, an activ-
ity of 131I above detection limit was found in ten (62.5%) of 
the examined individuals. In these individuals, measured 
activities ranged from (9 ± 3) Bq up to (1140 ± 295) Bq. In 
the group of children, in one case (25%) the activity of 131I 
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in the thyroid was above the detection limit and reached 
(58 ± 15) Bq. The difference in the number of results above 
detection limit—25% vs. 62.5%—as well as the difference 
in maximum activities (51 ± 14  Bq vs. 1140 ± 295  Bq) 
observed among children and adults might be explained 
by an increased concern about the safety of children in all 
aspects of everyday life.
Interestingly, the maximum measured activity reached, 
1140 ± 295 Bq, is relatively high. For comparison, in a sepa-
rate study it was shown that the maximum activity of 131I in 
the thyroid of medical staff who work with radioiodine on a 
daily basis reached only 217–457 Bq (Brudecki et al. 2017a, 
2018b). The reason for such a high 131I activity in the thyroid 
of the husband of a female patient (see Table 1) may be the 
fact that the treated patient was bedridden and in need of 
continuous care by the tested relative.
As mentioned earlier, the measured 131I activities were 
statistically analysed along with the results of surveys of the 
individuals participating in the study, by means of CA and 
nonparametric tests: Mann–Whitney, gamma, χ2 and Yule 
Phi coefficient. The results are summarized in Tables 2, 3
Based on the performed analysis it can be concluded that 
the level of 131I activity in the thyroid of the examined indi-
viduals is primarily affected by their housing conditions. The 
gamma correlation analysis allowed to quantify the relation-
ship between thyroid activity and the number of rooms in 
the apartment (Rγ = – 0.767, p < 0.05). Next, χ2 and Yule 
Phi tests suggested concomitance between 131I activity in 
the thyroid and the following parameters: living in a city or 
on the countryside, the surface area of the apartment, con-
sumption of meals prepared by the patient, living in a sin-
gle-family house or in a flat, as well as sharing a bathroom 
with the patient (Table 2). This means that the 131I activity 
depends on whether the patients and their relatives live in a 
city or on the countryside. Specifically, it was found that 131I 
activity in thyroids of relatives living in the city was higher 
than that of relatives living on the countryside. This could be 
explained taking into consideration that people in cities have 
typically less living space available than people on the coun-
tryside (for example in terms of surface area of the rooms, 
Table 1  131I thyroid activity among family members of patients 
treated with radioactive iodine (thyroid activity uncertainties were 
calculated by means of uncertainty propagation method)
A, adults, U, underage, M, male, F, female
Code Gender Personal relation-
ship with patients 
treated with 131I
Type of treatment 131I thyroid 
activity 
[Bq]
A1 M Husband Thyroid cancer 9 ± 3
A2 M Son Thyroid cancer < 4
A3 F Daughter Hyperthyroidism 51 ± 14
A4 M Husband Thyroid cancer < 5
A5 F Wife Thyroid cancer 341 ± 88
A6 M Husband Hyperthyroidism 1140 ± 295
A7 F Daughter Thyroid cancer 20 ± 6
A8 M Husband Hyperthyroidism 98 ± 25
A9 M Husband Thyroid cancer 151 ± 39
A10 F Wife Thyroid cancer 10 ± 3
A11 F Sister Thyroid cancer < 4
A12 M Husband Thyroid cancer < 4
A13 F Wife Thyroid cancer 557 ± 144
A14 M Husband Hyperthyroidism 72 ± 19
A15 M Son Hyperthyroidism < 5
A16 M Husband Hyperthyroidism < 6
U1 F Daughter Thyroid cancer 58 ± 15
U2 M Son Thyroid cancer < 10
U3 F Daughter Thyroid cancer < 11
U4 M Son Thyroid cancer < 5
Table 2  Results of statistical 
analyses for dichotomous 
variables
a categorized sum of surfaces of all floors




Thyroid activity Living in city or in countryside 5.05 0.025 0.503
Thyroid activity Surface  areaa of apartment 5.09 0.024 − 0.504
Thyroid activity Consumption of meals prepared by patient 7.01 0.008 0.592
Thyroid activity living in single-family house or in flat 8.81 0.030 0.664
Thyroid activity Bathroom sharing with the patient 13.39 0.000 0.818
Table 3  Association weights based on the correspondence analysis 
model [Thyroid activity III—elevated activities (≥ 150 and < 600 Bq), 
Thyroid activity IV—highly elevated values (> 1100 Bq)]
Pairs of associated parameters weight
Thyroid activity IV Consumption of meals prepared by 
patient
0.96
Thyroid activity III Number of rooms in apartment 0.87
Thyroid activity IV Bathroom sharing with the patient 0.87
Thyroid activity IV Frequent contact with patients 0.85
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number of bathrooms). Moreover, higher 131I activities were 
observed in relatives living in flats (as compared to those 
living in single family houses), as well as in the situations 
when the meals were prepared by patients and the bathroom 
was shared with them. Conducted CA analyses confirmed 
the above-mentioned findings, and in addition, revealed a 
connection between 131I activity in relatives’ thyroid and 
the frequency of their contacts with the patients (Table 3).
The difference in thyroid activities of family members 
of patients either with cancer or hyperthyroidism was not 
statistically significant. However, the number of examined 
individuals was low and, consequently, one should treat this 
result with caution.
The highest observed activity in the thyroid 
(1140 ± 295 Bq) corresponds to an effective dose of only 
218 µSv, while the thyroid equivalent dose was 2.4 mSv. 
In the group of children, the maximum effective dose and 
thyroid equivalent dose reached 13 µSv and 0.16 mSv, 
respectively. These doses are relatively low, keeping in mind 
that the maximum effective dose of 218 µSv is only about 
9% of the mean annual effective dose due to natural radia-
tion sources in Poland, which may suggest that there will 
be no discernible negative consequences for the health of 
the examined individuals. In addition, the estimated doses 
are also significantly lower than the external doses found 
in other studies for relatives of patients treated with 131I 
(Mathieu et al. 1999; Pant et al. 2005; Kocovska et al. 2011a, 
b; Zehtabian et al. 2017).
Conclusions
So far, the issue of internal contamination was mainly 
associated with people who work with open radioactive 
sources on a daily basis (e.g., medical staff). The current 
study showed that internal contamination may also affect 
relatives of patients treated with radiopharmaceuticals. Even 
though 131I activities in thyroids of the investigated relatives 
could be detected in some cases (up to about 1000 Bq), the 
related doses are rather low, i.e., less than 218 µSv, which is 
less than about 9% of the mean annual effective dose due to 
natural radiation sources in Poland, which is about 2.48 mSv 
per year (Janik and Tokonami 2009). In the light of current 
knowledge it is concluded that internal doses received by 
family members of patients treated with 131I will not result 
in any discernable negative health consequences.
In addition, the results of the statistical analyses per-
formed in the present study revealed relationships between 
131I activities in the thyroids of some of the investigated indi-
viduals and their housing conditions (number of rooms, sur-
face area of apartments, whether or not a bathroom is shared 
with a patient discharged from hospital after treatment 
with 131I) as well as consumption of meals prepared by the 
patient. Knowledge of such facts may lead to an improve-
ment in the radiological protection of patients’ relatives in 
the future.
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